1Ben Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children’s Research Institute, Seattle, Washington.

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Cancer Signaling & Microenvironment Program, Marvin and Concetta Greenberg Pancreatic Cancer Institute, Fox Chase Cancer Center, Lewis Katz School of Medicine, Temple Health, Philadelphia, ...

Cancer Immunology Research, launched in 2013 with Glenn Dranoff as founding Editor-in-Chief, is published by the AACR. The Journal illuminates the interplay between tumors and the immune system, with ...

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...

1Department of Radiation Oncology, Stanford University, Stanford, California. 2Stanford Cancer Institute, Stanford University, Stanford, California.

The German drug company Merck KGaA will purchase the oncology biotech SpringWorks Therapeutics for $3.9 billion, in a deal that is expected to close in the second half of the year. Based in Stamford, ...

WRN inhibitor development is burgeoning, with four candidates now in phase I trials. First-in-human findings on one, RO7589831, indicate that the drug is safe, well tolerated, and shows promising ...

1Instituto de Investigación Sanitaria HM Hospitales, Madrid, Spain. 2Department of Basic Medical Sciences, Institute of Applied Molecular Medicine (IMMA), Facultad de Medicina, Universidad San Pablo ...

1Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. 5Department of Medical Biophysics, University of Toronto, Toronto, Canada. 6Department of Medicine, University of Toronto, ...

The investigational HER2-selective tyrosine kinase inhibitor zongertinib appears remarkably effective in patients with HER2-mutant non–small cell lung cancer. Robust, durable responses were seen in ...

1Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois. *Corresponding Author: Hilary A. Kenny, Department of Obstetrics and Gynecology, ...